Fusidic acid
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Fusidic acid structure.svg | |
| Fusidic acid
| |
| Systematic (IUPAC) name | |
| 2-(16-acetyloxy-3,11-dihydroxy-4,8,10,14- tetramethyl- 2,3,4, 5,6,7, 9,11,12, 13,15,16- dodecahydro- 1H-cyclopenta [a]phenanthren-17-ylidene) -6-methyl- hept-5-enoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | D06 D09AA02 J01XC01 |
| PubChem | |
| Chemical data | |
| Formula | C31H48O6 |
| Mol. mass | 516.709 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Fusidic acid | |
|
Articles | |
|---|---|
|
Most recent articles on Fusidic acid Most cited articles on Fusidic acid | |
|
Media | |
|
Powerpoint slides on Fusidic acid | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Fusidic acid at Clinical Trials.gov Clinical Trials on Fusidic acid at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Fusidic acid
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Fusidic acid Discussion groups on Fusidic acid Patient Handouts on Fusidic acid Directions to Hospitals Treating Fusidic acid Risk calculators and risk factors for Fusidic acid
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Fusidic acid | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Fusidic acid is a bacteriostatic antibiotic that is often used topically in creams and eyedrops, but may also be given systemically as tablets or injections.
Pharmacology
Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. Fusidic acid is only effective on gram-positive bacteria such as Staphylococcus species and Corynebacterium species. Fusidic acid inhibits bacterial replication and does not kill the bacteria, and is therefore termed "bacteriostatic".
Fusidic acid is a true antibiotic, derived from the fungus Fusidium coccineum and was developed by Leo Laboratories in Ballerup, Denmark and released for clinical use in the 1960s. It has also been isolated from Mucor ramannianus and Isaria kogana. The drug is not licensed for use in the US, but, as sodium fusidate, it is approved for use under prescription in the UK, Europe Australia and New Zealand.
Uses
Fusidic acid is active in vitro against Staphylococcus aureus, most coagulase-negative staphylococci, Corynebacterium species, most clostridium species. Fusidic acid has no useful activity against streptococci, enterococci or most Gram-negative bacteria (except Neisseria, Moraxella, Legionella pneumophila and Bacteroides fragilis). Fusidic acid is active in vitro and clinically against Mycobacterium leprae but has only marginal activity against Mycobacterium tuberculosis.
The most important use of fusidic acid clinically is its activity against Methicillin Resistant Staphylococcus Aureus, a sometimes-fatal 'hospital-acquired 'superbug'.[1] Many strains of MRSA remain sensitive to fusidic acid, but because there is a low genetic barrier to resistance (a single point mutation is all that is required), fusidic acid must never be used on its own to treat MRSA and should be combined with another antimicrobial such as rifampicin.
Fusidic acid is often found in topical skin and eye preparations (e.g., Fusibet®), a use which has been contested.[1]
Dosing
Fusidic acid should not be used on its own to treat Staph. aureus infections. The use of topical preparations (skin creams and eye ointments) containing fusidic acid is strongly associated with the development of resistance,[1] and there are voicing agitating against the continued use of fusidic acid monotherapy in the community.[1] Topical preparations used in Europe often contain fusidic acid and gentamicin in combination, which helps to prevent the development of resistance.
Depending on the reason for which sodium fusidate is prescribed the adult dose can be 250 mg twice a day and or up to 750 mg three times a day. (Skin conditions normally need the smaller dose). It is available in tablet and suspension form.[1] There is an intravenous preparation available but it is irritant to veins, causing phlebitis. Most people absorb the drug extremely well after taking it orally so, if a patient can swallow, there is not much need to administer it intravenously, including endocarditis (infection of the heart chambers).
Pregnancy caution
'There is inadequate evidence of safety in human pregnancy. Animal studies and many years of clinical experience suggest that fusidic acid is devoid of teratogenic effects (birth defects)...fusidic acid can cross the placental barrier.[1]
Side Effects
- 'Fucidin®) Tablets and Suspension can occasionally cause liver upsets which can produce jaundice (yellowing of a patient's skin and the whites of his or her eyes). This condition will almost always get better after you finish taking Fucidin®) Tablets or Suspension.
Other related side effects include dark urine, lighter-than-usual feces. These, too should normalize when the course of treatment is completed.'[1]
- Patients taking the drug should tell their doctors if they notice that their urine is 'very dark', their feces is 'very pale' or if their skin or the whites of their eyes becomes yellow, the Australian data sheet for patients adds.
Resistance
Because the drug is not licensed for use in the US, and there are therefore no Clinical and Laboratory Standards Institute standard definitions of fusidic acid resistance.
In the UK and Australia, susceptibility is defined as an MIC of 0.25mg/l or 0.5mg/l or less. Resistance is defined as an MIC of 2mg/l or more. In laboratories using disc diffusion methods, susceptibility for a 2.5µg disc is defined as a zone of 22 mm or more, and resistance is defined as a zone of 17 mm or less; intermediate values are defined as intermediate resistance.
Mechanisms of resistance have only been extensively studied in Staphylococcus aureus. The most important mechanism is the development of point mutations in fusA, the chromosomal gene which codes for EF-G. The mutation alters EF-G so that fusidic acid is no longer able to bind to it.[1][1] Resistance is readily acquired when fusidic acid is used alone and commonly develops during the course of treatment, but resistance does not occur when fusidic acid is used in combination with other antibiotics.[1] For this reason, fusidic acid should not be used on its own to treat Staph. aureus infections.
Some bacteria also mediate resistance via the fusB gene, which is carried on a plasmid; the mechanism by which fusB causes resistance is unknown.
Interactions
Fusidic acid must not be used with quinolones, with which they are antagonistic. When combined with rifampicin, the action of fusidic acid is additive or synergistic.[1]
It is delivered as an ointment, a cream, eye drops or in tablet form.
Trade names and preparations
- Fusidin (of Leo in Canada)
- Fucidin (of Leo in UK/ Leo-Ranbaxy-Croslands in India)
- Fucidine (of Leo in France)
- Fucithalmic (of Leo in UK and Denmark)
- Fucicort (topical mixture with hydrocortisone)
- Fucibet (topical mixture with betamethasone)
References
Antibiotics and chemotherapeutics for dermatological use (D06) | |
|---|---|
| Antibiotics: tetracycline and derivatives | Demeclocycline - Chlortetracycline - Oxytetracycline - Tetracycline |
| Antibiotics: other | Fusidic acid - Chloramphenicol - Neomycin - Bacitracin - Gentamicin - Tyrothricin - Mupirocin - Nadifloxacin - Virginiamycin - Rifaximin - Amikacin |
| Chemotherapeutics: sulfonamides | Silver sulfadiazine - Sulfathiazole - Mafenide - Sulfamethizole - Sulfanilamide - Sulfamerazine |
| Chemotherapeutics: antivirals | Idoxuridine - Tromantadine - Aciclovir - Podophyllotoxin - Inosine - Penciclovir - Lysozyme - Ibacitabine - Edoxudine - Imiquimod - Docosanol |
| Chemotherapeutics: other | Metronidazole |
Medicated dressings (D09) |
|---|
| Framycetin - Fusidic acid - Nitrofural - Phenylmercuric nitrate - Benzododecinium - Triclosan - Cetylpyridinium - Aluminium chlorohydrate - Povidone-iodine - Clioquinol - Benzalkonium - Chlorhexidine - Iodoform |
Antibacterials for systemic use: others (J01X) | |
|---|---|
| Glycopeptide | Vancomycin (Oritavancin, Telavancin) - Teicoplanin (Dalbavancin) |
| Polymyxins | Colistin - Polymyxin B |
| Steroid antibacterials | Fusidic acid |
| Imidazole derivatives | Metronidazole - Tinidazole - Ornidazole |
| Nitrofuran derivatives | Nitrofurantoin - Nifurtoinol |
| Other | -mycin (Fosfomycin, Spectinomycin, Daptomycin, Hitachimycin) Xibornol - Clofoctol - Methenamine - Iclaprim - Mandelic acid - Nitroxoline - Linezolid |
Cholestanes, membrane lipids: sterols |
|---|
| Adosterol - Cholecalciferol/Ergocalciferols - Cholesterol - Dihydrotachysterol - Fusidic acid - Lanosterol - Phytosterols - Solanine |
de:Fusidinsäure hu:Fuzidinsav nl:Fusidinezuur
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
